Zenkuda and Tabirafusp-Ted Meet Primary Endpoints in Pivotal Daybreak Trial in Wamd, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-Week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.